AI assistant
ILIKA PLC Regulatory Filings 2021
7701_mang_2021-04-08_0ad72dbd-b46c-4f21-b54d-b1c0b4324eff.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 7399U
Ilika plc
08 April 2021
Ilika plc
("Ilika", or the "Company")
Appointment of Berenberg as Joint Corporate Broker
Ilika (AIM: IKA) a pioneer in solid-state battery technology, announces the appointment of Berenberg as the Company's Joint Broker with immediate effect.
Berenberg will work alongside the Company's existing Nomad and Broker, Liberum Capital Limited.
| For more information contact: Ilika plc |
www.ilika.com | |
| Graeme Purdy, Chief Executive Officer | Via Walbrook PR | |
| Steve Boydell, Finance Director | ||
| Liberum Capital Limited (Nomad and Joint Broker) | Tel: 020 3100 2000 | |
| Andrew Godber, Cameron Duncan, William Hall, Nikhil Varghese | ||
| Berenberg (Joint Broker) | Tel: 020 3207 7800 | |
| Emily Morris, Detlir Elezi, Alamgir Ahmed, Milo Bonser |
||
| Walbrook PR Ltd | Tel: 020 7933 8780 / [email protected] | |
| Tom Cooper | Mob: 0797 122 1972 | |
| Lianne Cawthorne | Mob: 07584 391 303 | |
| Nick Rome | Mob: 07748 325 236 | |
About Ilika:
Ilika plc (AIM: IKA) is a pioneer in solid state battery technology with their innovative Stereax micro batteries designed for next-generation MedTech markets, and their Goliath large format batteries for the electric vehicle and consumer electronics markets. Ilika works closely with its ecosystem of partners to provide customisable Stereax micro batteries and develop its Goliath Wh-level solid state battery pouches and cells. The company is building a consortium of global expertise with its Goliath Leader Partnership program.
Find more about Ilika and their innovative solid state battery technology at www.ilika.com and on Twitter at @ilikaplc.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPEAKLXEAAFEFA